Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. / Petersen, T R; Bregenholta, S; Pedersen, L O; Nissen, Mogens Holst; Claesson, M H.
In: Cancer Letters, Vol. 137, No. 2, 1999, p. 183-91.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice.
AU - Petersen, T R
AU - Bregenholta, S
AU - Pedersen, L O
AU - Nissen, Mogens Holst
AU - Claesson, M H
N1 - Keywords: Animals; COS Cells; Cytotoxicity Tests, Immunologic; Dendritic Cells; Gene Expression; HLA-A2 Antigen; Humans; Immunity, Cellular; Immunodominant Epitopes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Peptide Fragments; T-Lymphocytes, Cytotoxic; Transfection; Tumor Suppressor Protein p53; Vaccines, DNA
PY - 1999
Y1 - 1999
N2 - C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.
AB - C57BL/10 mice transgenic for HLA-A2 were immunized with either a full-length DNA-construct of the tumor suppressor p53 or with a minigene encoding the p53-derived immunodominant peptide p53(264)LLGRNSFEV272 (L9V). Vaccination with the full-length p53 construct induced potent cytotoxic activity of splenocytes against L9V-pulsed target cells after in vivo re-stimulation. Vaccination with the L9V-encoding minigene likewise induced specific anti-L9V cytotoxicity in vitro. Subsequent experiments revealed that peptide-pulsed dendritic cells were the most efficient cell types for in vitro re-stimulation. In concordance with this, immunization with L9V-pulsed dendritic cells also induced a potent and specific anti-L9V cytotoxic response in vitro. These data show that HLA-A2/peptide-specific cytotoxic immunity can be generated in vivo against the same immunodominant epitope by immunizing either with full-length DNA or with a DNA minigene encoding the immunodominant peptide epitope.
M3 - Journal article
C2 - 10374840
VL - 137
SP - 183
EP - 191
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
IS - 2
ER -
ID: 8746407